1. Home
  2. TNXP vs LGI Comparison

TNXP vs LGI Comparison

Compare TNXP & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$9.92

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Logo Lazard Global Total Return and Income Fund

LGI

Lazard Global Total Return and Income Fund

HOLD

Current Price

$18.13

Market Cap

237.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
LGI
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
237.7M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
TNXP
LGI
Price
$9.92
$18.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
544.8K
30.1K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
7.10%
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$10.03
$15.32
52 Week High
$69.65
$19.88

Technical Indicators

Market Signals
Indicator
TNXP
LGI
Relative Strength Index (RSI) 35.99 44.22
Support Level N/A $17.32
Resistance Level $13.18 $18.37
Average True Range (ATR) 0.93 0.24
MACD -0.22 -0.07
Stochastic Oscillator 1.20 12.75

Price Performance

Historical Comparison
TNXP
LGI

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

Share on Social Networks: